Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: A systematic review and economic evaluation

Health Technology Assessment

Volumn 15, Issue 10, 2011, Pages 134-

  Rodgers, M ^a   Epstein, D ^a   Bojke, L ^a   Yang, H ^a   Craig, D ^a   Fonseca, T ^a   Myers, L ^a   Bruce, I ^b   Chalmers, R ^b   Bujkiewicz, S ^c   Lai, M ^c   Cooper, N ^c   Abrams, K ^c   Spiegelhalter, D ^d   Sutton, A ^c   Sculpher, M ^a   Woolacott, N ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; BRONCHITIS; CELLULITIS; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED CANCER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; INFECTION; INFLUENZA; INJECTION SITE REACTION; LUPUS LIKE SYNDROME; NAUSEA; OUTCOME ASSESSMENT; PHARYNGITIS; PNEUMONIA; PREVALENCE; PROGNOSIS; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY ADJUSTED LIFE YEAR; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT INFECTION; RHINITIS; RHINOPHARYNGITIS; RISK FACTOR; SIDE EFFECT; SINUSITIS; SYSTEMATIC REVIEW; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; COST; ECONOMICS; PATHOLOGY; REVIEW; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED KINGDOM;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; COSTS AND COST ANALYSIS; GREAT BRITAIN; HUMANS; IMMUNOGLOBULIN G; PROGNOSIS; QUALITY-ADJUSTED LIFE YEARS; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 79951609399     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta15100     Document Type: Article

References (247)

1. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64(Suppl. II):ii,14-17.
2. Helliwell PS, Taylor WJ. Classification and diagnostic criteria for psoriatic arthritis. Ann Rheum Dis 2005;64(Suppl. II):ii,3-8.
3. Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol 2003;4:441-7.
4. Kay LJ, Parry-James JE, Walker DJ. The prevalence and impact of psoriasis and psoriatic arthritis in the primary care population in North East England. Arthritis Rheum 1999;42(Suppl.):299.
5. Harrison BJ, Silman AJ, Barrett EM, Scott DG, Symmons DP. Presence of psoriasis does not influence the presentation or short-term outcome of patients with early inflammatory polyarthritis. J Rheumatol 1997;24:1744-9.
6. Feuchtenberger M, Kleinert S, Tony HP, Kneitz C. Psoriatic arthritis: therapeutic principles. Clin Dermatol 2008;26:460-3.
7. Ruderman E. Evaluation and management of psoriatic arthritis: the role of biologic therapy. J Am Acad Dermatol 2003;49(Suppl. 2A):125-32.
8. Patel S, Veale D, FitzGerald V, McHugh N. Psoriatic arthritis: emerging concepts. Rheumatology 2001;40:243-6.
9. Krueger G. Clinical features of psoriatic arthritis. Am J Manag Care 2002;8(Suppl. 6):160-70.
10. Galadari H, Fuchs B, Lebwohl M. Newly available treatments for psoriatic arthritis and their impact on skin psoriasis. Int J Dermatol 2003;42:231-7.
11. Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JYM, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008;58:851-64.
12. Gladman D. Effectiveness of psoriatic arthritis therapies. Semin Arthritis Rheum 2003;33:29-37.
13. Pipitone N, Kingsley G, Manzo A, Scott D, Pitzalis C. Current concepts and new developments in the treatment of psoriatic arthritis. Rheumatology 2003;42:1138-48.
14. Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology 2003;42:1460-8.
15. Husted J, Gladman D, Long J, Farewell V. A modified version of the Health Assessment Questionnaire (HAQ) for psoriatic arthritis. Clin Exp Rheumatol 1995;13:439-43.
16. Gladman D, Hing E, Schentag C, Cook R. Remission in psoriatic arthritis. J Rheumatol 2001;28:1045-8.
17. Gottlieb A. Psoriatic arthritis: a guide for dermatology nurses. Dermatol Nurs 2003;15:107-19.
18. McHugh N, Balachrishnan C, Jones S. Progression of peripheral joint disease in psoriatic arthritis: a 5-year prospective study. Rheumatology 2003;42:778-83.
19. Gladman D, Stafford-Brady F, Chang C, Lewandowski K, Russell M. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 1990;17:809-12.
20. Queiro-Silva R, Torre-Alonso J, Tinture-Eguren T, Lopez-Lagunas I. A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis. Ann Rheum Dis 2003;62:68-70.
21. Gladman D, Farewell V. The role of HLA antigens as indicators of disease progression in psoriatic arthritis Multivariate relative risk model. Arthritis Rheum 1995;38:845-50.
22. Lindqvist URC, Alenius G-M, Husmark T, Theander E, Holmstrom G, Larsson PT, et al. The Swedish early psoriatic arthritis register: 2-year follow-up: a comparison with early rheumatoid arthritis. J Rheumatol 2008;35:668-73.
23. Moll J, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973;3:55-78.
24. Mease P, Goffe B. Diagnosis and treatment of psoriatic arthritis. J Am Acad Dermatol 2005;52:1-19.
25. Borman P, Toy GG, Babaoǧlu S, Bodur H, Ciliz DAN. A comparative evaluation of quality of life and life satisfaction in patients with psoriatic and rheumatoid arthritis. Clin Rheumatol 2007;26:330-4.
26. Husted J, Gladman D, Farewell V, Cook R. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthrit Care Res 2001;45:151-8.
27. Curran S, Winchester R, Costello P, Peterson K, Bresnihan B, FitzGerald O. Methotrexate therapy reduces polyclonal T cell infiltration in the psoriaitc arthritis synovium, revealing expanded CD4 and CD8 T-cell clones. Arthritis Rheum 1999;42:S372.
28. Haake H, Koneke J, Amann K, vom Dahl J, Janssen U. [Development of systemic lupus erythematosus with focal proliferative lupus nephritis during anti-TNF-alpha therapy for psoriatic arthritis]. Med Klin 2007;102:852-7.
29. Wong K, Gladman DD, Husted J, Long J, Farewell VT. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. Causes and risk of death. Arthritis Rheum 1997;40:1868-72.
30. Gladman D, Farewell V, Wong K, Husted J. Mortality studies in psoriatic arthritis: results from a single outpatient center. II Prognostic indicators for death. Arthritis Rheum 1998;41:1103-10.
31. Ali Y, Tom BD, Schentag CT, Farewell VT, Gladman DD. Improved survival in psoriatic arthritis with calendar time. Arthritis Rheum 2007;56:2708-14.
32. Williams JP, Meyers JA. Immune-mediated inflammatory disorders (I.M.I.D.s): the economic and clinical costs. Am J Manag Care 2002;8:S664-81.
33. Huscher D, Merkesdal S, Thiele K, Ziedler H, Schneider M, Zink A. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematous in Germany. Ann Rheum Dis 2006;65:1175-83.
34. Jonsson B, Rehnberg C, Borgquist L, Larsson S. Locomotion status and costs in destructive rheumatoid arthritis. A comprehensive study of 82 patients from a population of 13,000. Acta Orthop Scand 1992;63:207-12.
35. Kvien T. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 2004;22:1-12.
36. Pugner K, Scott D, Holmes J, Hieke K. The costs of rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum 2000;129:305-20.
37. Feldman S, Fleischer A, Reboussin D, Rapp S, Bradham D, Clark A. The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol 1997;37:564-9.
38. Jonsson B, Kaarela K, Koblet G. Economic consequences of the progression of rheumatoid arthritis: a Markov model. Stockholm: Stockholm School of Economics; 1997.
39. Kobelt G, Eberhardt K, Jonsson L, Jonsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999;42:347-56.
40. McIntosh E. Clinical audit: the cost of rheumatoid arthritis. Br J Rheumatol 1996;35:781-90.
41. Kobelt G, Jonsson L, Lindgren P, Young A, K. E. Modelling the progression of rheumatoid arthritis:a two-country model to estimate costs to estimate costs and consequences of rheumatoid arthritis. Arthritis Rheum 2002;46:2310-19.
42. Michaud K, Messer J, Choi H, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis. Arthritis Rheum 2003;48:2750-62.
43. Armstrong D, McCausland E, Wright G. The impact of anti-TNF-alpha therapy on the nature of service provision. Rheumatology 2006;45:112.
44. Goldsmith C, Smythe H, Helewa A. Interpretation and power of a pooled index. J Rheumatol 1993;20:575-8.
45. Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009;301:737-44.
46. Felson D, Anderson J, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
47. Felson D, Anderson J, Lange M, Wells G, LaValley M. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum 1998;41:1564-70.
48. Gladman DD, Helliwell P, Mease PJ, Nash P, Ritchlin C, Taylor W. Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum 2004;50:24-35.
49. Clegg D, Reda D, Mejias E, Cannon G, Weisman M, Taylor T, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39:2013-20.
50. McHugh N, Chandler D, Griffiths C, Helliwell P, Lewis J, McInnes I, et al. BSR guideline for anti-TNFa therapy in psoriatic arthritis. London: British Society for Rheumatology; 2004.
51. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89.
52. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72.
53. Wassenberg S, Fischer-Kahle V, Herborn G, Rau R. A method to score radiographic change in psoriatic arthritis. Z Rheumatol 2001;60:156-66.
54. Jones G, Crotty M, Brooks P. Interventions for treating psoriatic arthritis. Cochrane Database Syst Rev 2000;3:CD000212. DOI: 10.1002/14651858.CD000212.
55. Taccari E, Spadaro A, Rinaldi T, Riccieri V, Sensi F. Comparison of the Health Assessment Questionnaire and Arthritis Impact Measurement Scale in patients with psoriatic arthritis. Rev Rhum 1998;65:751-8.
56. Blackmore M, Gladman D, Husted J, Long J, Farewell V. Measuring health status in psoriatic arthritis: the Health Assessment Questionnaire and its modification. J Rheumatol 1995;22:886-93.
57. Wong J, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med 2002;113:400-8.
58. Haroon M, Bond U, Phelan M. Sinusitis: a possible link with adalimumab. Clin Rheumatol 2008;27:1189-90.
59. Kobelt G, Jonsson L, Young A, Eberhardt K. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology 2003;42:326-35.
60. Marguerie L, Flipo R, Grardel B, Beaurain D, Duquesnoy B, Delcambre B. Use of diseasemodifying antirheumatic drugs in patients with psoriatic arthritis. Joint Bone Spine 2002;69:275-81.
61. Alldred A, Emery P. Leflunomide: A novel DMARD for the treatment of rheumatoid arthritis. Expert Opin Pharmacother 2001;2:125-37.
62. Kaltwasser J, Nash P, Gladman D. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psorisasis. Arthritis Rheum 2004;50:1939-50.
63. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999;159:2542-50.
64. Nash P, Clegg D. Psoriatic arthritis and psoriasis: treatment. Ann Rheum Dis 2005;64 (Suppl. 2):ii, 74-7.
65. British Medical Association and Royal Pharmaceutical Society of Great Britain. British national formulary. No. 58, 2009. London: BMA and RPS; 2009.
66. NHS Business Services Authority. Prescribing analysis charts. 2009. URL: www.nhsbsa.nhs. uk/PrescriptionServices/2585.aspx (cited 13 November 2009).
67. Gorter S, van der Heijde DMFM, van der Linden S, Houben H, Rethans J-J, Scherpbier AJJA, et al. Psoriatic arthritis: performance of rheumatologists in daily practice. Ann Rheum Dis 2002;61:219-24.
68. Pariser D. Management of moderate to severe plaque psoriasis with biologic therapy. Manag Care 2003;12:36-44.
69. Gniadecki R, Zachariae C, Calverley M. Trends and developments in the pharmacological treatment of psoriasis. Acta Derm Venereol 2002;82:401-10.
70. Prinz J. The role of T cells in psoriasis. J Eur Acad Derm Venereol 2003;17:257-70.
71. Cvetkovic RS, Scott LJ. Adalimumab: a review of its use in adult patients with rheumatoid arthritis. Biodrugs 2006;20:293-311.
72. The NHS Information Centre. Hospital prescribing, 2008: England. URL: www.ic.nhs.uk/ (cited 13 November 2009).
73. Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, et al. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 2006;10(46).
74. NICE Evidence Review Group. Adalimumab for the treatment of moderate to severe psoriatic arthritis. London: NICE; 2009.
75. Centre for Reviews and Dissemination (CRD). Manual for selecting reviews and writing abstracts for the Database of Abstracts of Reviews of Effects (DARE). 2008. URL: www.crd. york.ac.uk/crdweb/html/help.htm.
76. Moher D, Cook D, Eastwood S, Olkin I, Rennie D, Stroup D. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet 1999;354:1896-900.
77. Higgins J, Whitehead J. Borrowing strength from external trials in meta-analysis. Stat Med 1996;15:2733-49.
78. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90.
79. Centocor. A multicenter placebo-controlled, double-blind, randomised study of anti-TNF chimeric monoclonal antibody (cA2, infliximab) in patients with active psoriatic arthritis (IMPACT): protocol no P02114 [industry submission]. Malvern, PA: Centocor; 2003.
80. Schering-Plough Ltd. Remicade in the treatment of psoriatic arthritis in the United Kingdom: a submission to the National Institute for Clinical Excellence [industry submission]. Kenilworth, NJ: Schering-Plough Ltd; 2004.
81. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005;52:1227-36.
82. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150-7.
83. Genovese MC, Mease PJ, Thomson GT, Kivitz AJ, Perdok RJ, Weinberg MA, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol 2007;34:1040-50.
84. Genovese MC, Mease PJ, Thomson GTD, Kivitz AJ, Perdok RJ, Weinberg MA. Adalimumab efficacy in patients with psoriatic arthritis who failed prior DMARD therapy [abstract FRI0187]. Ann Rheum Dis 2005;64(Suppl. III):313.
85. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Choy EHS, Steinfeld SD, et al. Clinical efficacy and safety of adalimumab for psoriatic arthritis: 48-week results of ADEPT [abstract 500]. Arthritis Rheum 2005;52(Suppl. 9):215.
86. Mease PJ, Sharp JT, Ory PA, Gladman DD, Richlin CT, Choy EH. Adalimumab treatment effects on radiographic progression of joint disease in patients with psoriatic arthritis: results from ADEPT (abstract FRI0212). Ann Rheum Dis 2005;64(Suppl. III):320.
87. ®) is effective and safe in treating psoriatic arthritis (PsA) in real-life clinical practice: preliminary results of the STEREO trial. Annual Scientific Meeting of the American College of Rheumatology, Washington, DC, 10-15 November 2006.
88. Mease PJ, Ory P, Sharp JT, Ritchlin CT, Van den Bosch F, Wellborne F, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009;68:702-9.
89. Antoni CE, Kavanaugh A, van der Heijde D, Beutler A, Keenan G, Zhou B, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 2008;35:869-76.
90. van der Heijde D, Kavanaugh A, Gladman DD, Antoni C, Krueger GG, Guzzo C, et al. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum 2007;56:2698-707.
91. Kavanaugh A, Krueger GG, Beutler A, Guzzo C, Zhou B, Dooley LT, et al. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 2007;66:498-505.
92. Gladman DD, Mease PJ, Ritchlin CT, Choy EHS, Sharp JT, Ory PA, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 2007;56:476-88.
93. Gladman DD, Mease PJ, Cifaldi MA, Perdok RJ, Sasso E, Medich J. Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Ann Rheum Dis 2007;66:163-8.
94. Vander Cruyssen B, De Keyser F, Kruithof E, Mielants H, Van den Bosch F. Comparison of different outcome measures for psoriatic arthritis in patients treated with infliximab or placebo. Ann Rheum Dis 2007;66:138-40.
95. Kavanaugh A, Antoni C, Mease P, Gladman D, Yan S, Bala M, et al. Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis. J Rheumatol 2006;33:2254-9.
96. Kavanaugh A, Antoni CE, Gladman D, Wassenberg S, Zhou B, Beutler A, et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 2006;65:1038-43.
97. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006;33:712-21.
98. Kavanaugh A, Antoni C, Krueger GG, Yan S, Bala M, Dooley LT, et al. Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. Ann Rheum Dis 2006;65:471-7.
99. Fleischmann R, Baumgartner SW, Weisman MH, Liu T, White B, Peloso P. Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis 2006;65:379-84.
100. Choy E, Gladman D, Sasso E. Efficacy of adalimumab by disease duration in psoriatic arthritis: subanalysis of ADEPT (abstract P2748). J Am Acad Dermatol 2007;56:186.
101. Gladman D, Mease P, Ritchlin C, Okun M. PASI-100 is associated with better dermatologyspecific patient-reported outcomes compared with PASI-75e99 in adalimumab-treated patients with psoriatic arthritis: subanalysis of ADEPT (abstract P2746). J Am Acad Dermatol 2007;56:185.
102. Gladman D, Mease P, Kavanaugh A, Weinberg M. Adalimumab is efficacious in treating skin disease in psoriatic arthritis: subanalysis of moderate versus severe psoriasis in the ADEPT trial (abstract P40). J Am Acad Dermatol 2006;54:10-11.
103. Mease P, Gladman D, Ritchlin C, Weinberg M. Clinical efficacy, safety and inhibition of joint destruction of adalimumab in the treatment of moderate to severe psoriatic arthritis: 48-week results of the ADEPT trial (abstract P2865). J Am Acad Dermatol 2006;54:214.
104. Mease P, Sharp J, Ory P, Gladman D, Ritchlin C, Choy E, et al. Adalimumab treatment effects on radiographic progression of joint disease in patients with psoriatic arthritis: results from ADEPT (abstract P06.12). J Eur Acad Dermatol Venereol 2005;19(Suppl. 2):163.
105. Lebwohl M, Gottlieb A, Goffe BS, Jahreis A. Etanercept in psoriatic arthritis: sustained improvement in skin and joint disease and inhibition of radiographic progression at 2 years [abstract 155-09]. J Am Acad Dermatol 2005;52:8.
106. Papp K, Menter A, Antoni C, Kavanaugh A, Gottlieb AB, Poulin Y, et al. Rapid and persistent improvement of psoriasis in patients with active psoriatic arthritis treated with infliximab: 24-week results of the impact 2 trial (abstract P028). J Eur Acad Dermatol Venereol 2004;18:783.
107. Wanke LA, Mease PJ, Gottlieb AB. Sustained improvement in functional status and vitality of psoriatic arthritis patients treated with etanercept (abstract 382). J Invest Dermatol 2004;122:64.
108. Sterry W, Ortonne JP, Kirkham B, Robertson D, Molta C, Pedersen R, et al. Results of a randomized, double-blind study to evaluate the efficacy and safety of etanercept in patients with psoriasis and psoriatic arthritis: the PRESTA trial (abstract P29). Br J Dermatol 2008;159:1410-11.
109. Kavanaugh A, Krueger GG, Birbara C, Halter D, Geusens P, de Vlam K, et al. Treatment with infliximab is associated with 'major clinical response' in psoriatic arthritis patients treated with infliximab: analysis of two double-blind placebo controlled trials (abstract OP0104). Ann Rheum Dis 2006;65(Suppl. 2):85.
110. Mease PJ, Woolley M, Singh A, Tsuji W, Dunn M, Chiou CF. Patient-reported outcomes in a randomized comparison of etanercept and placebo for treatment of psoriatic arthritis (abstract SAT0279). Ann Rheum Dis 2006;65(Suppl. 2):535.
111. Kavanaugh A, Krueger GG, Birbara C, Halter D, Geusens P, de Vlam K, et al. Treatment with infliximab is associated with 'major clinical response' in psoriatic arthritis patients treated with infliximab: analysis of two double-blind placebo controlled trials (abstract 121). J Invest Dermatol 2007;127:1824.
112. Kavanaugh A, Krueger GG, Birbara C, Halter D, Geusens P, de Vlam K, et al. Treatment with infliximab is associated with 'major clinical response' in psoriatic arthritis patients treated with infliximab: analysis of two double-blind placebo controlled trials (abstract L18). Arthritis Rheum 2005;52:4065.
113. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu ZN, Burmester G, Schneider U, et al. Twoyear data: infliximab maintains clinical response in psoriatic arthritis patients: data from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT) (abstract 485). Arthritis Rheum 2005;52(Suppl. S):209.
114. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, et al. Twoyear data: Infliximab maintains clinical response in psoriatic arthritis patients - an analysis of the year 2 data from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT) (abstract OP0080). Ann Rheum Dis 2005;64(Suppl. 3):82.
115. Antoni CE, Kavanaugh A, Gladman D, Wassenberg S, Zhou B, Beutler A, et al. The infliximab multinational psoriatic arthritis controlled trial (IMPACT): results of radiographic analyses after 1 year [abstract OP0156]. Ann Rheum Dis 2005;64(Suppl. 3):107.
116. Kavanaugh A, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, et al. Infliximab significantly improves joint and skin involvement in psoriatic arthritis to a substantial extent and irrespective of baseline joint involvement or MTX use: analysis of clinical response from the IMPACT2 trial (abstract 1637). Arthritis Rheum 2004;50(Suppl. S):617.
117. Antoni CE, Kavanaugh A, Kirkham B, Burmester G, Manger B, Tutuncu Z, et al. The infliximab multinational psoriatic arthritis controlled trial (IMPACT): substantial efficacy on synovitis and psoriatic lesions with or without concomitant DMARD therapy (abstract OP0082). Ann Rheum Dis 2003;62(Suppl. 1):90.
118. Antoni CE, Kavanaugh A, Kirkham B, Burmester G, Manger B, Schneider U, et al. The infliximab multinational psoriatic arthritis controlled trial (IMPACT1): the concomitant use of DMARDs does not influence the efficacy and safety of infliximab over a one year period (abstract SAT0083). Ann Rheum Dis 2004;63(Suppl. 1):411-12.
119. Fidder H, Schnitzler F, Ferrante M, Noman M, Katsanos K, Segaert S, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009;58:501-8.
120. Klareskog L, Gaubitz M, Rodriguez-Valverde V, Malaise M, Dougados M, Wajdula J. A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs. Ann Rheum Dis 2006;65:1578-84.
121. Moreland LW, Weinblatt ME, Keystone EC, Kremer JM, Martin RW, Schiff MH, et al. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J Rheumatol 2006;33:854-61.
122. Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52:3403-12.
123. Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatolog Treat 2004;15:280-94.
124. Colombel J-F, Loftus EV, Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004;126:19-31.
125. Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 2009;68:519-25.
126. Rudwaleit M, Olivieri I, Boki KA, Griep EN, Jarvinen P, Wong RL, et al. Adalimumab is effective and well tolerated in treating patients with ankylosing spondylitis who have advanced spinal fusion. Rheumatology 2009;48:551-7.
127. Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009;58:492-500.
128. Caspersen S, Elkjaer M, Riis L, Pedersen N, Mortensen C, Jess T, et al. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol 2008;6:1212-17.
129. Favalli EG, Desiati F, Atzeni F, Sarzi-Puttini P, Caporali R, Pallavicini FB, et al. Serious infections during anti-TNF alpha treatment in rheumatoid arthritis patients. Autoimmun Rev 2009;8:266-73.
130. Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008;67:189-94.
131. Burmester GR, Mariette X, Montecucco C, Monteagudo-Saez I, Malaise M, Tzioufas AG, et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis 2007;66:732-9.
132. Gomez-Reino JJ, Carmona L, Descalzo MA. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007;57:756-61.
133. Colombel J, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65.
134. Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007;56:1125-33.
135. Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 2006;43:717-22.
136. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DPM. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-76.
137. Oka H, Nishioka K, Togo M, Ochi T. The efficacy of infliximab for patients with rheumatoid arthritis in Japan: results of 5000 cases by post-marketing surveillance data. APLAR J Rheum 2006;9:142-5.
138. Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:889-94.
139. Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P, et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 2006;54:1075-86.
140. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, Van Vollenhoven R, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
141. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, Montero D, Pascual-Gomez E, Mola EM, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005;52:1766-72.
142. Feltelius N, Fored CM, Blomqvist P, Bertilsson L, Geborek P, Jacobsson LT, et al. Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. Ann Rheum Dis 2005;64:246-52.
143. St. Clair EW, Van Der Heijde DMFM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432-43.
144. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004;50:372-9.
145. Nahar IK, Shojania K, Marra CA, Alamgir AH, Anis AH. Infliximab treatment of rheumatoid arthritis and Crohn's disease. Ann Pharmacother 2003;37:1256.
146. Gomez-Reino JJ, Carmona L, Rodriguez Valverde V, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48:2122-7.
147. Dixon WG, Symmons DPM, Lunt M, Watson KD, Hyrich KL, British Society for Rheumatology Biologics Register Control Centre Consortium, et al. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007;56:2896-904.
148. Dreyer L, Mellemkjaer L, Hetland ML. [Cancer in arthritis patients after anti-tumour necrosis factor therapy]. Ugeskr Laeger 2009;171:506-11.
149. Kyle S, Chandler D, Griffiths CEM, Helliwell P, Lewis J, McInnes I, et al. Guideline for anti-TNF-alpha therapy in psoriatic arthritis. [Erratum appears in Rheumatology (Oxford) 2005;44:569.] Rheumatology 2005;44:390-7.
150. Mease P, Ganguly R, Wanke L, Yu E, Singh A. How much improvement in functional status is considered important by patients with active psoriatic arthritis: applying the outcome measures in rheumatoid arthritis clinical trials (OMERACT) group guidelines. Ann Rheum Dis 2004;63(Suppl. 1):391.
151. Abbott Laboratories Ltd. Adalimumab (HUMIRA): Multiple technology appraisal of adalimumab, etanercept and infliximab for psoriatic arthritis National Institute for Health and Clinical Excellence (NICE) Health Technology Appraisal. Maidenhead: Abbott Laboratories Ltd; 2009.
152. Schering-Plough. REMICADE (infliximab): Remicade in the treatment of Psoriatic Arthritis (PsA) in the United Kingdom. A submission to the National Institute of Clinical Excellence: Welwyn Garden City: Schering-Plough Ltd; 2009.
153. Wyeth Pharmaceuticals. Etanercept (ENBREL): Appraisal of the clinical and cost-effectiveness of etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis. An appraisal submission for the National Institute of Health and Clinical Excellence. Maidenhead: Wyeth; 2009.
154. Kavanaugh A, McInnes I, Mease P, Krueger DG, Gladman D, Gomez-Reino J. Golimumab, a new human tumour necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60:976-86.
155. Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009;373:633-40.
156. REVEAL (M03-656). Clincial study report. Abbott Laboratories. Data on File.
157. Sterry WEA. Results of a Randomised, Double-Blind Study to Evaluate the Efficacy and Safety of Etanercept in Patients With Psoriasis psoriatic Arthritis: The PRESTA Trial. Gene to Clinic Conference, 2009.
158. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85.
159. Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis 2009;68:1177-83.
160. Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2006;33:2398-408.
161. Ravindran V, Scott DL, Choy EH. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. Ann Rheum Dis 2008;67:855-59.
162. Saad AA, Symmons DPM, Noyce PR, Ashcroft DM. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol 2008;35:883-90.
163. Brimhall AK, King LN, Licciardone JC, Jacobe H, Menter A. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br J Dermatol 2008;159:274-85.
164. Sutton AJ, Duval SJ, Tweedie RL, Abrams KR, Jones DR. Empirical assessment of effect of publication bias on meta-analyses BMJ 2000;320:1574-7.
165. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet 1991;337:867-72.
166. Egger M, Zellweger-Zahner T, Schneider M, Junker C, Lengeler C, Antes G. Language bias in randomised controlled trials published in English and German. Lancet 1997:350:326-9.
167. Patsopoulos NA, Evangelou E, Ioannidis JP. Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol 2008;37:1148-57.
168. Thompson SG. Systematic Review: Why sources of heterogeneity in meta-analysis should be investigated BMJ 1994;309:1351-5.
169. Mohan AK, Cote TR, Block JA, Manadan AM, Siegel JN, Braun MM. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 2004;39:295-9.
170. Iliopoulos A, Psathakis K, Aslanidis S, Skagias L, Sfikakis PP. Tuberculosis and granuloma formation in patients receiving anti-TNF therapy. Int J Tuberc Lung Dis 2006;10:588-90.
171. Toussirot E, Streit G, Wendling D. Infectious complications with anti-TNFalpha therapy in rheumatic diseases: a review. Recent Pat Inflamm Allergy Drug Discov 2007;1:39-47.
172. Dumville J, Torgerson D, Hewitt C. Reporting attrition in randomised controlled trials. BMJ 2006;332:969-71.
173. Smith C, Anstey A, Barker J, Burden A, Chalmers R, Chandler D, et al. British Association of Dermatologists' Guidelines for Biologic Interventions for Psoriasis. Br J Dermatol 2009;161:987-1019.
174. Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess 2006;10(46).
175. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 2nd edn. New York, NY: Oxford University Press; 1997.
176. Bansback NJ, Ara R, Barkham N, Brennan A, Fraser AD, Conway P, et al. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis. Rheumatology 2006;45:1029-38.
177. Bravo Vergel Y, Hawkins NS, Claxton K, Asseburg C, Palmer S, Woolacott N, et al. The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis. Rheumatology 2007;46:1729-35.
178. Olivieri I, de Portu S, Salvarani C, Cauli A, Lubrano E, Spadaro A, et al. The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy. Rheumatology 2008;47:1664-70.
179. Turner D, Picot J, Cooper K, Loveman E. Adalimumab for the treatment of psoriasis. Health Technol Assess 2009;13(Suppl. 2):49-54.
180. Gray A, Rivero-Arias O, Clarke P. Estimating the association between SF-12 responses and EQ-5D utility values by response mapping. Med Decis Making 2006;26:18-29.
181. Brazier JE, J. R. The estimation of a preference-based measure of health from the SF-12. Med Care 2004;42:851-9.
182. NICE. TA104 Psoriatic arthritis, etanercept and infliximab - guidance. London: NICE; 2006.
183. NICE. TA125 Psoriatic arthritis (moderate to severe) - adalimumab: guidance. London: NICE; 2007.
184. NICE. Updated guide to the methods of technology appraisal. London: NICE; 2008.
185. The NHS Information Centre. Health Survey for England 2007: adult trends tables. London: NHS; 2008.
186. Saad A, Ashcroft D, Watson K, Symmonds D, Noyce P, Hyrich K. Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-TNF therapies. Arthritis Care Res 2010;62:345-53.
187. Department of Health (DoH). Reference costs 2007-08. London: DoH; 2009.
188. Hartman M, Prins M, Swinkels OQJ, Severens JL, De Boo T, Van Der Wilt GJ, et al. Costeffectiveness analysis of a psoriasis care instruction programme with dithranol compared with UVB phototherapy and inpatient dithranol treatment. Br J Dermatol 2003;147:538-44.
189. Spiegel D. Placebos in practice. BMJ 2004;329:927-8.
190. Gulfe A, Kristensen L, Saxne T, Jacobsson L, Petersson I, Geborek P. Rapid and sustained health utility gain in anti-TNF treated inflammatory arthritis. Observational data during seven years in southern Sweden. Ann Rheum Dis 2010;69:352-7.
191. Saad A, Ashcroft D, Watson K, Hyrch K, Noyce P, Symmons D. Persitence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observation study from the British Society for Rheumatology Biologics register. Arthritis Res Ther 2009;11:112.
192. Poyner T, Wall A, Adnitt P, Menday A. Economic impact of psoriasis treatment on the patient and on the National Health Service. J Dermatolog Treat 1999;10:25-9.
193. Prodanowich S, Fangchao M, Taylor J, Pezon C, Fasihi T, Kirsner R. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. Am Acad Dermatol 2005;52:670.
194. Finlay A. Current severe plaque psoriasis and the rule of tens. Br J Dermatol 2005;152:861-7.
195. Reich K, Mrowietz U. Treatment goals in psoriasis. JDDG 2007;5:556-74.
196. Hyrich K, Lunt M, Watson K, Symmons D, Silman A. Outcomes after switching from one anti tumor necrosis factor alpha agent in patients with rheumatoid arthritis. Results from a large UK national cohort study. Arthritis Rheum 2007;56:13-20.
197. Johannesson M, Weinstein S. On the decision rules of cost-effectiveness analysis. J Health Econ 1993;12:459-67.
198. Geborek P, Bladstrom A, Turesson C, Gulfe A, Petersson IF, Saxne T, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005;64:699-703.
199. Malesci D, Tirri R, Buono R, G. LM. Leflunomide in psoriatic arthritis: a retrospective study of discontinuation rate in daily clinical practice compared with methotrexate. Rheumatol 2007;25:881-4.
200. Mease P. TNF-alpha therapy in psoriatic arthritis and psoriasis. Ann Rheum Dis 2004;63:755-8.
201. Scott DL, Pugner K, Kaarela K, Doyle DV, Woolf A, Holmes J, et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatol Int 2000;39:122-32.
202. Lefebvre C, Manheimer E, Glanville J. Searching for studies. In Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions, version 5.0.1 (updated September 2008). Oxford: The Cochrane Collaboration; 2008.
203. Wong S, Wilczynski N, Haynes R. Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE. J Med Libr Assoc 2006;94:41-7.
204. Centre for Reviews and Dissemination (CRD) Identifying studies for inclusion in NHS EED. 2009. URL: www.crd.york.ac.uk/crdweb/html/helpdoc.htm#item17 (cited 11 June 2009).
205. Sutton A, Ades A, Cooper N, Abrams KR. Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics 2008;26:753-67.
206. Ades A, Welton N, Caldwell D, Price M, Goubar A, Lu G. Multiparameter evidence synthesis in epidemiology and medical decision-making. J Health Serv Res Policy 2008;13:12-22.
207. Lunn DJ, Thomas A, Best N, Spiegelhalter D. Winbugs: a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 2000;10:325-37.
208. Jansen J, Crawford B, Bergman G, Stam W. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health 2008;11:956-64.
209. Ades A, Lu G, Higgins J. The interpretation of random-effects meta-analysis in decision models. Med Decis Making 2005;25:646-54.
210. Fahrmeir L, Tutz G. Multivariate statistical modelling based on generalized linear models. New York, NY: Springer-Verlag; 2001.
211. Wailoo AJ, Bansback N, Brennan A, Michaud K, Nixon RM, F W. Biologic drugs for rheumatoid arthritis in the Medicare Program. Arthritis Rheum 2008;58:939-46.
212. Kind P. The EuroQol instrument: An index of health-related quality of life. In Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. 2nd edition. Philadelphia: Lippincott-Raven Publishers; 1996. pp. 191-201.
213. Fraser AD, van Kuijk AW, Westhovens R, Karim Z, Wakefield R, Gerards AH, et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 2005;64:859-64.
214. Aletaha D, Stamm T, Kapral T, Eberl G, Grisar J, Machold KP, et al. Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study. Ann Rheum Dis 2003;62:944-51.
215. Kristensen LE, Gulfe A, Saxne T, Geborek P. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Ann Rheum Dis 2008;67:364-9.
216. Monthly Index of Medical Specialties (MIMS). July 2009. URL: www.mims.co.uk/home/.
217. Curtis L. Unit costs of health and social care 2008. London: PSSRU; 2008.
218. Hrobjartsson A, Gotzsche P. Placebo interventions for all clinical conditions. Cochrane Database Syst Rev 2004;3:CD003974.
219. Bedford T, Cooke R. Probabilistic risk analysis: foundations and methods. Cambridge: Cambridge University Press; 2004.
220. Garthwaite PH, Kadane JB, O'Hagan A. Statistical methods for eliciting probability distributions. J Am Stat Assoc 2005;100:680-700.
221. O'Hagan A, Buck CE, Daneshkhah A, Eiser JR, Garthwaite PH, Jenkinson DJ, et al. Uncertain judgements: eliciting experts' probabilities. Chichester: Wiley; 2006.
222. van Noortwijk JM, Dekker R, Cooke RM, Mazzuchi TA. Expert judgement in maintenance optimization. IEEE T Reliab 1992;41:427-32.
223. Cooke RM. Experts in uncertainty: opinion and subjective probability in science. New York, NY: Oxford University Press; 1991.
224. Genest C, Zidek JV. Combining probability distributions. Stat Sci 1986;1:114-47.
225. Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting. Stat Med 2000;21:2917-30.
226. Heiberg MS, Koldingsnes W, Mikkelsen K, Rodevand E, Kaufmann C, Mowinckel P, et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum 2008;59:234-40.
227. Heiberg MS, Kaufmann C, Rodevand E, Mikkelsen K, Koldingsnes W, Mowinckel P, et al. The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study. Ann Rheum Dis 2007;66:1038-42.
228. Gomez-Reino JJ, Carmona L, Group B. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006;8:R29.
229. Lu G, Ades A, Sutton A, Cooper N, Briggs A, Caldwell D. Meta-analysis of mixed treatment comparisons at multiple follow up times. Stat Med 2007;26:3681-99.
230. Department of Health (DoH). Reference costs 2008-09. London: DoH; 2010.
231. Morgan C, Lunt M, Bunn D, Scott DGI, Symmons DPM. Five-year outcome of a primarycare- based inception cohort of patients with inflammatory polyarthritis plus psoriasis. Rheumatology 2007;46:1819-23.
232. OECD. Purchasing power parities 2005-2008. URL: www.oecd.org/dataoecd/61/54/18598754.pdf
233. Wiles N, Cooper N, Symmons D. Resource use within the Norfolk Arthritis Register (NOAR) Cohort during the first five years of disease: report for Roche (NICE Data on File). London: NICE; 2005.
234. Sizto S, Bansback N, Feldman S, Willian M, Anis A. Economic evaluation of systemic therapies for moderate to severe psoriasis. Br J Dermatol 2009;160:1264-72.
235. Lloyd A, Reeves P, Conway P, Reynolds A, Baxter G. Economic evaluation of etanercept in the management of chronic plaque psoriasis. Br J Dermatol 2008;160:380-6.
236. Colombo G, Altomare G, Peris K, Martini P, Quarta G, Congedo M, et al. Moderate and severe plaque psoriasis: cost-of-illness study in Italy. Ther Clin Risk Manag 2008;4:559-68.
237. Marchetti A, LaPensee K, An P. A pharmacoeconomic analysis of topical therapies for patients with mild-to-moderate stable plaque psoriasis: a US study. Clin Ther 1998;20:851-69.
238. National Psoriasis Foundation. URL: www.psoriasis.org (cited 22 November 2009).
239. Gefland J, Troxel A, Lewis J, Kohli Kurd S, Shin D, Wang X, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007;143:1493-9.
240. Gagnon Y, Levy A, Spencer M, Hurley J, Frost F, Mapel D, et al. Economic evaluation of treating chronic obstructive pulmonary disease with inhaled corticosteroids and long-acting [beta]2-agonists in a health maintenance organization. Respir Med 2005;99:1534-45.
241. Coates LC, Cawkwell LS, Ng NWF, Bennett AN, Bryer DJ, Fraser AD, et al. Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience. Ann Rheum Dis 2008;67:717-19.
242. Carmona L, Gomez-Reino JJ. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER Group. Arthritis Res Ther 2006;8:R72.
243. Walkenbach J. Excel 2007 Bible. Indianapolis, IN: Wiley Publishing; 2007.
244. Walkenbach J. Excel 2007 Power programming with VBA. Indianapolis, IN: Wiley Publishing; 2007.
245. Baier T, Neuwirth E. Excel: COM:: R. Computational Statistics 2007;22:91-108.
246. Heiberger R, Neuwirth E. R through Excel: a spreadsheet interface for statistics, data analysis, and graphics. Hamden, CT: Springer; 2009.
247. Sturtz S, Ligges U, et al. R2WinBUGS: a package for running WinBUGS from R. J Stat Softw 2005;12:1-16.